Full-Time

Trade Account Specialist

Posted on 3/21/2026

Deadline 3/22/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$22.25 - $37.09/hr

+ Overtime eligibility

Memphis, TN, USA

Hybrid

Category
Sales & Account Management (1)
Required Skills
SAP Products
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree with 0+ years of experience; OR a high school diploma (or equivalent) and 4+ years of relevant experience in call center functions, understanding of debits/credits, deduction resolution and/or order processing.
  • Excellent verbal and written communication skills with demonstrated telephone skills.
  • Strong interpersonal skills in a multi-team environment required
  • Proficiency in Microsoft Office with a strong working knowledge of Excel.
Responsibilities
  • Perform assigned customer service tasks to ensure the highest quality of operational support for Pfizer’s major trade accounts.
  • Collaboratively engage customers on order analysis, forecast adjustment, inventory levels, and cycle time delays.
  • Sales Order Management transactional responsibilities include processing EDI orders, process claims for shipping exceptions, provide order tracking through carriers, and perform deduction research/reconciliation as necessary.
  • Extensive use of the data warehouse and SAP’s Business Objects application to review customer orders, analyze operational trends, and research customer reported issues.
  • Customer Account Specialist works collaboratively with internal resources including the customer operational analysis team that have responsibility overseeing the order management process for all branded accounts.
  • Participate in customer score carding processes and monthly operational alignment meetings (with buyers) which include possible customer site visits.
  • Proactively interacts with Supply chain on high impact orders, the warehouse (on shipping exceptions) as well as other internal stakeholders (deployment, traffic, acct, mgmt, etc…) to quickly resolve potential customer facing issues.
  • Closely work with customers (assigned buyers) to identify and communicate relevant market-related data and competitive intelligence to Pfizer’s supply chain and customer operations team as necessary.
  • Research complex claims. Work collaboratively with customers , deduction specialist and the credit department to resolve deductions which include DSA failure to supply, shipping discrepancies, pricing, returns, to name a few.
  • Maintains a detailed working knowledge of Pfizer’s trade policies, SOPs and standard business processes and consistently applies that knowledge to daily operational tasks.
  • Proactively work with management to address exception situations.
  • Positively represent Pfizer by providing exceptional customer service to a wide range of external customers including consumers, pharmaceutical buyers, and medical professionals.
  • Handles both internal and 800 calls as well as email correspondence in a professional and punctual manner.
  • Communicates policy and has a strong working knowledge of Pfizer’s product line.
  • Team player to include: Excellent communicator. Provides operational assistance to customers and internal clients that support the attainment of business objectives.
  • Assist both customers and CSR colleagues with escalated inquiries or problems, increasing the ability to provide our customers with prompt resolution
  • Support special projects as assigned including claims initiatives, collection efforts, and miscellaneous internal and external requests
  • Successfully operate in a collaborative team environment, ensuring individual/team metrics, & working to improve quality while maintaining respect for people.
  • Collaborate with management team to examine practices and procedures as part of a continuous business improvement effort.
Desired Qualifications
  • Experience in SAP ERP, Sales Order Management
  • Experience working in pharmaceutical industry
  • Account management experience

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE